Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.1.1.17 (
ornithine decarboxylase
)
6,351
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Degradation provides one means for controlling the cellular level of the p53 tumor suppressor. Here we have determined a structural element of p53 required for degradation. To create a substrate amenable to in vitro analysis of proteolysis, we appended to p53 the N terminus of antizyme, a protein that binds to and induces degradation of mammalian
ornithine decarboxylase
(
ODC
). We found using deletion analysis that an element within amino acids 100-150 is required for degradation of the fusion protein. A monoclonal antibody (PAb246) that binds close to this region prevents the degradation induced by human papillomavirus 16
E6 protein
. Furthermore, we found that amino acids 100-150 of p53 can function as an independent domain to induce Trypanosoma brucei
ODC
, a stable protein, to be degraded in vivo or, by cooperating with an antizyme binding domain of
ODC
, to confer polyamine-dependent regulation.
...
PMID:Identification of a region of p53 that confers lability. 862 97
